Zal Bilimoria

Background

Zal Bilimoria is the founding partner and sole general partner of Refactor Capital, a seed-stage venture capital firm based in Burlingame, California ¹. He co-founded Refactor in 2016 with David Lee, formerly managing partner at SV Angel ². When Lee stepped back to become Chairman in 2019 and Rick Barber (the third co-founder) departed, Bilimoria became the sole GP — a structure he has maintained by design ³⁴.

Bilimoria grew up in Northwest Indiana, where his father, an Indian immigrant and metallurgical engineer, ran a computer business on the side. Bilimoria has described himself as “conscripted child labor from age six onwards,” helping his father build and sell computers ⁵. His father went on to found five companies ⁵.

Bilimoria earned a BS in Economics from the Wharton School at the University of Pennsylvania ⁶⁷. After graduating, he spent approximately a decade as a product manager at major technology companies, including Microsoft (his first role out of college), Google, YouTube, Netflix, and LinkedIn ⁵⁸. At Netflix, he led the redesign of the iPad app, which he has described as highly successful in driving streaming hours ⁵.

Around 2010, Bilimoria co-founded Sniply, a startup that attempted to rebuild Google Reader using Twitter as a distribution channel. Despite receiving a $2 million seed offer, the founders declined and shut the company down after recognizing insurmountable distribution challenges ⁵.

In 2013, Bilimoria joined Andreessen Horowitz as a partner ⁷. Originally tasked with finding the next major consumer or enterprise application, he was drawn into digital health by founders he met, and volunteered to lead a16z’s health investment efforts ¹⁹. His interests expanded into computational and synthetic biology, and in 2015 he helped launch a16z’s first Bio Fund ¹⁸. He left a16z in early 2016 to co-found Refactor Capital ⁷.

Since becoming sole GP, Bilimoria has raised three additional funds: Fund II at $36 million (closed May 2019), Fund III at $50 million, and Fund IV at $50 million (closed June 2024 in under 90 days, with approximately 90% of capital from existing investors) ³⁴¹⁰. Across all funds and SPVs, Refactor manages approximately $225 million in assets ¹⁸.

Stated Thesis

(Self-reported: These represent what Bilimoria says publicly about his approach. See Inferred Thesis for analysis of actual investment behavior.)

Bilimoria publicly describes Refactor’s mission as backing founders who are “refactoring the real world” — applying the computer science concept of refactoring to physical-world industries ¹¹⁰. He has stated the firm is built around “a simple belief: the most enduring companies are created by founders willing to commercialize real science” ⁸.

On his investment focus, Bilimoria has said: “These fundamental human problems are those that typically reside within traditionally regulated industries” ⁹. His stated thesis, as described on Signal by NFX, is “Biology is eating the world” ⁷.

The firm publicly states it invests in hard tech companies across aerospace, energy, biology, earth systems, and physical AI, while avoiding med-tech devices, single-asset therapeutics, traditional enterprise software, and consumer mobile apps ¹.

On founder selection, Bilimoria has stated: “Are they technically and commercially gifted? Are they going to be magnets for three types of people, customers, talent, and investors?” ⁵. He has also said: “The scientist founders we meet have to be incredible storytellers” ⁹.

Bilimoria emphasizes his solo GP model as a feature: “Being a solo GP gives me the ability to make lightning fast decisions — often producing term sheets in 3 weeks or less” ⁸. He typically writes lead or co-lead checks of $1–2 million into pre-seed and seed rounds, targeting approximately 10% ownership ¹¹¹.

Inferred Thesis

Based on the 55 verified portfolio companies listed on Refactor’s portfolio page ¹², Bilimoria’s actual investment behavior shows the following patterns.

Sector distribution (55 verified companies): - Biotech/life sciences: 16 of 55 (29%) — drug discovery, genomics, cell therapy, therapeutics (64x Bio, Gencove, Loyal, Octant Bio, YourChoice Therapeutics, Parallel Bio, Adventris, Granza Bio, Vitra Bio, Phytoform, Epana Bio, Miist Therapeutics, Pilgrim Labs, BioRender, Orchid, TBC) - Health/wellness: 10 of 55 (18%) — digital health, healthtech, wellness (PathAI, Headspace, Picnic Health, Lucy, Ophelia Health, Vital Health, Akasa, Curative, Atlas, Able) - Critical materials/chemicals: 6 of 55 (11%) — biology-derived chemicals and materials (Checkerspot, Macro Oceans, Aether, Solugen, Berkeley Yeast, Knowde) - Energy: 5 of 55 (9%) — battery, nuclear, data center, powertrain (Lumindt, Network Ocean, Pila Energy, Hexium, Brelle) - Earth systems/climate: 4 of 55 (7%) — weather, flood insurance, land restoration, emissions (Causal Labs, Floodbase, Remedy Scientific, Thalo Labs) - Aerospace: 2 of 55 (4%) — satellite and spacecraft (Astranis, General Galactic) - Other/stealth: 12 of 55 (22%) — includes 6+ stealth companies

Stage distribution: Bilimoria invests almost exclusively at seed, with some pre-seed participation. Each fund targets 20–25 companies deployed over three years ¹⁰⁸.

Check size: $1–2 million lead or co-lead checks, targeting ~10% ownership ¹¹¹. Signal by NFX reports a range of $100K–$2M with a target of $1.5M ⁷.

Geographic focus: Primarily US-based companies ¹.

Founder profile patterns: Bilimoria gravitates toward scientist-founders commercializing academic research, university spinouts, and companies with deep IP or science-based moats. He has stated he evaluates whether founders are “technically and commercially gifted” and can attract customers, talent, and investors ⁵.

Notable patterns: - Biology is the dominant thread across the portfolio. Combined, biology-adjacent companies (biotech + health + critical materials) represent roughly 58% of verified investments (32 of 55). - Despite claiming to avoid enterprise software, the portfolio includes several software-heavy companies (BioRender, Knowde, Akasa, Vital Health), though these serve scientific or healthcare verticals rather than general enterprise. - Energy allocation has grown in recent funds, reflecting stated expansion into climate tech. - The portfolio has produced 4 unicorns (Astranis, Solugen, and two others) and exits including PathAI (acquired by Quest Diagnostics, 2024), Betty Labs/Locker Room (acquired by Spotify, 2021), and Coinbase (IPO) ¹²¹³¹⁴.

Co-investor patterns: Frequent co-investors include Y Combinator, Social Capital, Fifty Years, BoxGroup, and Kindred Ventures ³¹⁵¹⁶.

Note: This analysis is based on 55 companies visible on Refactor’s portfolio page, representing roughly half of the 100+ total claimed investments. The full portfolio may show different distributions.

Portfolio

Note: Years marked with “~” are estimates based on company founding dates or fund deployment timelines, not confirmed investment dates. Entries without a confirmed round type reflect seed-stage investments consistent with the firm’s strategy. This table represents approximately half of Refactor’s 100+ total investments.

In Their Own Words

“I’m excited to continue backing founders solving hard but not impossible problems in an effort to create a better future for society. Being a solo capitalist allows me to move fast, build trust quickly, and work closely with founders reshaping industries. Investment decisions are at my sole discretion, allowing me to make decisions in a matter of days — not weeks or months. Founders have me on speed dial and receive all my attention along with Refactor’s $1-2M investment.” — Zal Bilimoria, Refactor Capital Fund IV press release, June 2024 ¹⁰

“Being a solo GP gives me the ability to make lightning fast decisions — often producing term sheets in 3 weeks or less.” — Zal Bilimoria, Pulse2 interview ⁸

“I pick up the tab for mental health services, not only for founders but their employees as well.” — Zal Bilimoria, Pulse2 interview ⁸

“You have to be able to believe that every single investment you make can return the fund.” — Zal Bilimoria, 20VC podcast ⁹

“These fundamental human problems are those that typically reside within traditionally regulated industries.” — Zal Bilimoria, 20VC podcast ⁹

“We haven’t seen many dedicated seed funds in these areas, especially those like us, who want to be that largest check in the seed round.” — Zal Bilimoria, 20VC podcast ⁹

“I know the types of founders I want to invest in. I want to spend a lot of time with them. I want to create a concentrated portfolio of 20 to 25 companies every fund.” — Zal Bilimoria, Alejandro Cremades interview ⁵

“Are they technically and commercially gifted? Are they going to be magnets for three types of people, customers, talent, and investors?” — Zal Bilimoria, on founder evaluation, Alejandro Cremades interview ⁵

“We are only in the graces of this wonderful profession because of them.” — Zal Bilimoria, on founders, 20VC podcast ⁹

“We believe biology is eating the world, literally every portion of it.” — Zal Bilimoria, 20VC podcast ⁹

“I am the investment committee.” — Zal Bilimoria, The Times Tech Podcast ²⁰

What Founders Say

“Having Zal as an investor has been a game-changer for Solugen, both in our early days and now. He believed in us and our mission to decarbonize the chemicals industry from the start, and has offered so much hands-on support beyond just writing a check. That’s why I asked him to join our board. Whenever I call him, he picks up. It’s rare to find an investor who’s a true partner like Zal.” — Gaurab Chakrabarti, Co-Founder and CEO, Solugen, Refactor Capital Fund IV press release, June 2024 ¹⁰

“Less than 15% of VC firms reach a fourth fund. Zal’s consistent strategy of raising equal-sized funds while building strong founder relationships has proven successful.” — Kevin Irwin, CIO, Knollwood Investment Advisory (LP, not founder), Refactor Capital Fund IV coverage, June 2024 ²¹

Note: Only one independently sourced founder testimonial was found. The Chakrabarti quote appeared in a Refactor press release, which represents a biased source. Dedicated searches across Twitter/X, press coverage, and podcast transcripts did not surface additional verifiable founder quotes about their experience with Bilimoria.

Connections

• Board member, Solugen — since February 2017; alongside co-founders Gaurab Chakrabarti (CEO) and Sean Hunt (CTO) ¹⁰²²
• Board member, Omada Health ²²
• GP Advisor, Screendoor — since March 2024 ²²
• Former Partner, Andreessen Horowitz (2013–2016) — helped launch a16z Bio Fund ¹⁷
• Frequent co-investor with Y Combinator, Social Capital, Fifty Years, BoxGroup, Kindred Ventures ³¹⁵¹⁶

Sources